Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Do, Y.
Right arrow Articles by Nagarkatti, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Do, Y.
Right arrow Articles by Nagarkatti, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

International Immunology, Vol. 15, No. 11, pp. 1327-1340, November 2003
© 2003 Japanese Society for Immunology

Combined deficiency in CD44 and Fas leads to exacerbation of lymphoproliferative and autoimmune disease

Yoonkyung Do1, Asimah Q. Rafi-Janajreh, Robert J. Mckallip1, Prakash S. Nagarkatti2 and Mitzi Nagarkatti1

Departments of 1 Microbiology and Immunology and 2 Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298, USA

Correspondence to: M. Nagarkatti; E-mail: mnagark{at}hsc.vcu.edu
Transmitting editor: P. S. Ohashi

Patients with mutations in Fas develop autoimmune lymphoproliferative disease (ALPS), while their family members with similar mutations are often normal, thereby suggesting that additional factors may play a role in the development of ALPS. In the current study, we tested the role of CD44 in the development of lymphoproliferative disease by generating CD44–/–/Fas–/– mice, which failed to express CD44 and Fas, and compared them to CD44+/+/Fas–/– mice that expressed CD44, but not Fas. The results showed that CD44–/–/Fas–/– mice developed a more severe lymphoproliferative and autoimmune disease when compared to CD44+/+/Fas–/– mice. This was indicated by increased numbers of cells in their lymph nodes, and a greater proportion of B220+CD4–CD8– (double-negative) T cells as well as antibodies against single-stranded DNA and chromatin. The heightened severity of lymphoproliferative disease seen in CD44–/–/Fas–/– mice correlated with increased resistance of T cells, but not B cells, to undergo activation-induced cell death (AICD). The current study suggests that deficiency in CD44 in combination with a defect in one of the molecules involved in the death receptor family such as Fas can further down-regulate AICD, and exacerbate the lymphoproliferative and autoimmune disease.

Keywords: activation-induced cell death, apoptosis, autoantibody, double-negative T cells, lupus


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
R. S. Hauptschein, K. E. Sloan, C. Torella, R. Moezzifard, M. Giel-Moloney, C. Zehetmeier, C. Unger, L. L. Ilag, and D. G. Jay
Functional Proteomic Screen Identifies a Modulating Role for CD44 in Death Receptor-Mediated Apoptosis
Cancer Res., March 1, 2005; 65(5): 1887 - 1896.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.